METROGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METROGEL (METROGEL).
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
| Metabolism | Hepatic via glucuronidation and oxidation; metabolites excreted renally. |
| Excretion | Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor. |
| Half-life | 8-10 hours (terminal); increased to 20-30 hours in hepatic impairment. |
| Protein binding | Less than 20%; albumin. |
| Volume of Distribution | 0.25-0.85 L/kg; extensive tissue distribution including CSF. |
| Bioavailability | Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%. |
| Onset of Action | Topical: 2-3 weeks for rosacea improvement; intravenous: immediate for bacterial infections. |
| Duration of Action | Topical: continuous use required; intravenous: dosing every 6-8 hours (half-life dependent). |
| Molecular Weight | 171.15 |
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for topical or intravaginal use; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure. |
| Pediatric use | Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established. |
| Geriatric use | No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin. |
| 1st trimester | Metronidazole crosses the placenta. Limited human data in first trimester; some studies suggest possible increased risk of cleft lip/palate, though data are conflicting. Use only if clearly needed. |
| 2nd trimester | Generally considered acceptable if benefit outweighs risk. No evidence of major teratogenicity in second trimester. |
| 3rd trimester | Safe for use near term; avoid high-dose systemic therapy near delivery due to potential accumulation in fetal tissues. |
Clinical note
Comprehensive clinical and safety monograph for METROGEL (METROGEL).
| Placental transfer | Metronidazole readily crosses the placenta with fetal plasma concentrations reaching 50-100% of maternal levels. |
| Breastfeeding | Metronidazole is excreted into breast milk. Topical application results in minimal systemic absorption; breastfeeding is considered safe. For oral/IV use, discontinue breastfeeding for 12-24 hours after a single dose to reduce infant exposure. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to metronidazole or any componentHypersensitivity to other nitroimidazole derivativesFirst trimester of pregnancy (relative contraindication unless essential)
| Precautions | Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure. |
| Food/Dietary | No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) for topical use; L3 (Moderately Safe) for systemic use |
| Teratogenic Risk | Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear. |
| Fetal Monitoring | None routine; monitor for maternal adverse effects (GI, neurotoxicity); fetal monitoring only if maternal toxicity. |
| Fertility Effects | No known adverse effects on fertility or reproduction. |
| Clinical Pearls | MetroGel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; MetroGel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes. · Do not use cosmetics or other skin products on treated areas unless approved by your doctor. · Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light. · Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness. · If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects. · Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider. |